Medtronic Endovascular
Clinical trials sponsored by Medtronic Endovascular, explained in plain language.
A subsidiary of Medtronic, focused on endovascular devices.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New device for leg clots tested in first human survey Results expected Oct 2026 (estimated)
- New coil survey aims to improve blood vessel treatments Results expected Nov 2026 (estimated)
- Liquid plug could stop bleeding without surgery Results expected Apr 2027 (estimated)
-
Liquid plug could stop bleeding without surgery
Disease control Recruiting nowThis study tests a liquid agent called Onyx™ that is injected into arteries to block active bleeding outside the heart and brain. It includes 119 adults with severe bleeding from trauma, ulcers, or other causes. The goal is to see if it safely stops bleeding without needing furth…
Sponsor: Medtronic Endovascular • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New device for leg clots tested in first human survey
Knowledge-focused Recruiting nowThis study surveys doctors who use the Liberant system to remove fresh blood clots from leg arteries and veins. About 50 patients aged 22 or older will be treated within 72 hours of their procedure. The goal is to confirm the device is safe and works as intended.
Sponsor: Medtronic Endovascular • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC